...
首页> 外文期刊>Bone marrow transplantation >Successful unrelated umbilical cord blood transplantation in children with Shwachman-Diamond syndrome.
【24h】

Successful unrelated umbilical cord blood transplantation in children with Shwachman-Diamond syndrome.

机译:Shwachman-Diamond综合征患儿的成功无关脐带血移植。

获取原文
获取原文并翻译 | 示例
           

摘要

Shwachman-Diamond syndrome (SDS) is an autosomal recessive disorder characterized by pancreatic insufficiency and variable degrees of neutropenia. SDS patients are at risk of developing myelodysplasia, aplastic anemia, and leukemic transformation. The role and timing of allogeneic hematopoietic stem cell transplantation (HSCT) in SDS remain controversial. We report three SDS patients with severe aplasia transplanted using unrelated umbilical cord blood (UCB). Patients received melphalan (180 mg/m2), etoposide (1200 mg/m2), anti-thymocyte globulin (90 mg/kg), and total lymphoid irradiation (500 cGy); graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and prednisone. Myeloid engraftment occurred promptly with absolute neutrophil count >500 cells/mm3 on day 15 +/- 5 and all patients displayed 100% donor chimerism by 2 months post transplant. The major complication of transplant was GVHD, with all patients developing grade II or III acute GVHD, one progressing to chronic extensive GVHD.Patients are alive 309, 623, and 2029 days post transplant. Factors important in HSCT outcome for SDS may include transplantation at a young age, avoidance of cyclophosphamide, and adequate GVHD prophylaxis. Importantly, these cases also suggest that unrelated UCB, in the absence of a matched family member, is an excellent alternative stem cell source for SDS patients undergoing HSCT.
机译:Shwachman-Diamond综合征(SDS)是一种常染色体隐性遗传疾病,其特征是胰腺功能不全和中性粒细胞减少症的程度不同。 SDS患者有发展为骨髓增生异常,再生障碍性贫血和白血病转化的风险。异基因造血干细胞移植(HSCT)在SDS中的作用和时机仍存在争议。我们报告了三名使用不相关的脐带血(UCB)移植的严重发育不良的SDS患者。患者接受美法仑(180 mg / m2),依托泊苷(1200 mg / m2),抗胸腺细胞球蛋白(90 mg / kg)和总淋巴样照射(500 cGy);预防移植物抗宿主病(GVHD)包括环孢素和泼尼松。骨髓植入迅速发生,绝对中性粒细胞计数> 500细胞/ mm3在第15 +/- 5天,并且所有患者在移植后2个月都表现出100%的供体嵌合。移植的主要并发症是GVHD,所有患者均发展为II级或III级急性GVHD,其中一名进展为慢性广泛GVHD。患者在移植后309、623和2029天存活。对于SDS HSCT结果重要的因素可能包括年轻时的移植,避免使用环磷酰胺和适当的GVHD预防。重要的是,这些案例还表明,在没有匹配家庭成员的情况下,不相关的UCB是接受HSCT的SDS患者的绝佳替代干细胞来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号